Top Doctor Top Doctor
The Top Doctor award is a peer-nominated award for providers who give exceptional care.

David G. Maloney, MD, PhD

Medical Director, Cellular Immunotherapy
Seattle Cancer Care Alliance
Professor, Division of Medical Oncology
University of Washington School of Medicine
Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Medical Oncology
“It’s not enough to treat cancer — we want to rev up your immune system to cure it.”
— Dr. Maloney
Why do you conduct research?

When I was a student at Stanford University in the 1980s, I was part of a team that made an amazing discovery. We created a protein called a monoclonal antibody that targeted cancer cells without harming healthy ones. At the time, there were a lot of skeptics — most people thought that antibody research wasn’t worthwhile. But we persevered, and now monoclonal antibodies are an important part of therapy for a variety of cancers. That breakthrough made me hungry for more. What else could I discover about the immune system? Could we train it to go after tumors the same way it attacks viruses? Does it hold the key for curing cancer, once and for all? These are the questions that have driven my work.

How do you approach cancer treatment?

A treatment plan isn’t something that we devise in one short discussion. It’s an in-depth conversation that may stretch across multiple visits. We’ll consider factors such as your health, your age, your disease, your personal philosophy and what the latest research has to offer. Treatments are rapidly evolving, and I enjoy sharing these advances with you so that you can make the best decisions about your care. Whatever you choose, I’m dedicated to helping you achieve the best possible outcome.

Provider background

Specialty: Medical Oncology

Lymphoid cancers

As the medical director of the Bezos Family Immunotherapy Clinic at SCCA, I treat patients with lymphoid cancers, such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma and multiple myeloma. My expertise spans the use of antibodies (proteins in the immune system that fight invaders), vaccines and bone marrow transplants. In the 1990s, I led the development of the drug rituximab, the first antibody-based cancer treatment, and I was also part of the team that created the mini-transplant, a less intense form of the conventional stem cell transplant.

Today, my research is focused on developing new immunotherapies where a patient’s own T cells (immune cells) are modified with a molecule called a chimeric antigen receptor (CAR). This receptor directs a patient’s immune system to attack tumors. Known as CAR T-cell therapy, this approach has been remarkably effective in early-phase trials, even with very advanced cancers that resist other treatments.

Diseases treated

Education, experience and certifications
Undergraduate Degree
Whitworth College
Medical Degree
Stanford University School of Medicine
Brigham and Women's Hospital, Internal Medicine
Stanford University Medical Center, Internal Medicine
Board Certification
Internal Medicine, 1988; Medical Oncology 2019, American Board of Internal Medicine
Seattle Met's 2019 Top Doctors award

Dr. Maloney has been recognized as a Top Doctor in Seattle Met's annual survey multiple years in a row.


When to refer leukemia and lymphoma patients for CAR T-cell therapy
When to refer leukemia and lymphoma patients for CAR T-cell therapy

CAR T-cell therapy for leukemia and lymphoma patients can be an incredibly effective treatment. That means understanding when to refer a patient for treatment is critical.

Innovative approaches to lymphoma: clinical trials including CAR T-cell therapy, transplant, bispecific antibodies, novel kinase and checkpoint inhibitors
Innovative approaches to lymphoma: clinical trials including CAR T-cell therapy, transplant, bispecific antibodies, novel kinase and checkpoint inhibitors

As survival rates for lymphoma are improving, the first therapy is typically the most effective and important. But patients may need more than one therapy. SCCA has one of largest and most comprehensive multidisciplinary lymphoma teams in the nation, and the largest team in the Northwest.


Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Complete title
Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Large B-cell Lymphoma Patients with Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Study ID:
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
Complete title
Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release
Study ID:
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)
Complete title
A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)


Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.


SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

New Toxicity Grading Criteria Help Standardize Management of CAR T-Cell Therapy-Related AEs

SCCA’s David Maloney, MD, Ph.D. spoke with Oncology Nursing News about the newly standardized grading criteria to help regulate CAR T-cell therapy.

Standardized Guidelines Support Management Strategies of CAR T-Cell Therapy–Related Toxicities

SCCA’s Dr. David G. Maloney discussed how newly standardized grading criteria is integral to managing toxicity levels in cellular immunotherapy.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.


SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers